Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Anika Therapeutics (ANIK) EBITDA Margin: 2009-2024

Historic EBITDA Margin for Anika Therapeutics (ANIK) over the last 16 years, with Dec 2024 value amounting to -47.72%.

  • Anika Therapeutics' EBITDA Margin rose 8976.00% to -9.03% in Q3 2025 from the same period last year, while for Sep 2025 it was -28.61%, marking a year-over-year increase of 8325.00%. This contributed to the annual value of -47.72% for FY2024, which is 2030.00% up from last year.
  • Latest data reveals that Anika Therapeutics reported EBITDA Margin of -47.72% as of FY2024, which was up 29.84% from -68.02% recorded in FY2023.
  • Anika Therapeutics' 5-year EBITDA Margin high stood at 2.00% for FY2021, and its period low was -68.02% during FY2023.
  • For the 3-year period, Anika Therapeutics' EBITDA Margin averaged around -43.15%, with its median value being -47.72% (2024).
  • Per our database at Business Quant, Anika Therapeutics' EBITDA Margin crashed by 5,433bps in 2023 and then skyrocketed by 2,030bps in 2024.
  • Yearly analysis of 5 years shows Anika Therapeutics' EBITDA Margin stood at -17.34% in 2020, then soared by 1,935bps to 2.00% in 2021, then slumped by 1,569bps to -13.69% in 2022, then crashed by 5,433bps to -68.02% in 2023, then soared by 2,030bps to -47.72% in 2024.